Stocktoria
Lexaria Bioscience Corp. LEXX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2009-10-28
Lexaria Bioscience Corp. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 99.6% | 99.0% | 86.1% | 71.9% | 75.7% | 56.0% | 89.7% | 94.2% | 53.3% | -12.0% |
| Operating margin | -1683.0% | -1239.2% | -2888.5% | -2591.7% | -786.8% | — | — | — | — | -3136.8% |
| Net margin | -1686.0% | -1248.2% | -2946.4% | -2846.3% | -557.2% | -1062.2% | 1841.8% | 1523.2% | -3031.9% | -3136.8% |
| FCF margin | -1483.9% | -1077.4% | -2614.8% | -1929.8% | — | -681.0% | -1640.4% | — | -2429.2% | -1630.6% |
| Return on assets | -285.1% | -65.4% | -216.1% | -92.8% | -30.4% | -144.4% | 153.3% | 271.4% | -67.5% | -225.4% |
| Return on equity | -398.1% | -72.1% | -218.9% | -91.5% | -30.8% | -164.6% | 164.6% | 276.4% | -69.7% | -480.1% |
| Current ratio | 2.32 | 7.18 | 8.03 | 35.96 | 81.18 | 8.53 | 9.86 | 52.34 | 30.27 | 1.18 |
Computed from company filings · US · as of 2025-08-31. Facts plus Stocktoria's own computed scores — not investment advice.